-transparent.png){kind=logo}
Host CD73 impairs anti-tumor immunity. 2012
MediCity Research Laboratory; University of Turku; Turku, Finland ; Department of Medical Biochemistry and Genetics; University of Turku; Turku, Finland ; National Institute of Health and Welfare; Tykistökatu; Turku, Finland.
The enzymatic activity of CD73 produces immune-suppressing adenosine. In CD73 deficient hosts, tumor growth and tumor infiltration by Tregs and type 2 immunosuppressive macrophages is reduced. Pharmacological inhibition of CD73 in wild-type mice has similar tumor-suppressing effects. Host CD73 on leukocytes and endothelial cells is thus detrimental for the anti-tumor immunity.
| UI | MeSH Term | Description | Entries |
|---|
Related Publications
Marko Salmi, and
Sirpa Jalkanen
March 2014,
International journal of cancer,
Marko Salmi, and
Sirpa Jalkanen
November 2014,
Oncotarget,
Marko Salmi, and
Sirpa Jalkanen
September 1992,
Yonsei medical journal,
Marko Salmi, and
Sirpa Jalkanen
April 1986,
Infusionstherapie und klinische Ernahrung,
Marko Salmi, and
Sirpa Jalkanen
January 2017,
Cancer immunology, immunotherapy : CII,
Marko Salmi, and
Sirpa Jalkanen
April 2024,
Future oncology (London, England),
Marko Salmi, and
Sirpa Jalkanen
November 2016,
Cell metabolism,
Marko Salmi, and
Sirpa Jalkanen
March 1990,
Journal of immunology (Baltimore, Md. : 1950),
Marko Salmi, and
Sirpa Jalkanen
September 2012,
Journal of immunology (Baltimore, Md. : 1950),
Marko Salmi, and
Sirpa Jalkanen
January 2023,
Cancer management and research,
